Pascal Turlure

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Sylvie Castaigné, Cécile Pautas, Christine Terré et al. · The Lancet · 2012 · 995 citations

Medicine, Hematology, Pharmacology +10

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

Jean‐Jacques Kiladjian, Bruno Cassinat, Sylvie Chevret et al. · Blood · 2008 · 570 citations · Full text

Medicine, Hematology, Pharmacology +7

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Raphaël Itzykson, Sylvain Thépot, Bruno Quesnel et al. · Blood · 2010 · 386 citations · Full text

Medicine, Oncology, Pharmacology +10

Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

Juliette Lambert, Cécile Pautas, Christine Terré et al. · Haematologica · 2018 · 352 citations · Full text

Medicine, Oncology, Pharmacology +15

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

A.-L. Taksin, Ollivier Legrand, Emmanuel Raffoux et al. · Leukemia · 2006 · 288 citations

Medicine, Oncology, Pharmacology +10